Kyverna Therapeutics (KYTX) Competitors $2.78 -0.06 (-2.11%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.80 +0.02 (+0.68%) As of 02/21/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KYTX vs. MLYS, TRDA, RNAC, HUMA, ARCT, SNDL, KALV, PROK, ABVX, and ORGOShould you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Mineralys Therapeutics (MLYS), Entrada Therapeutics (TRDA), Cartesian Therapeutics (RNAC), Humacyte (HUMA), Arcturus Therapeutics (ARCT), SNDL (SNDL), KalVista Pharmaceuticals (KALV), ProKidney (PROK), ABIVAX Société Anonyme (ABVX), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. Kyverna Therapeutics vs. Mineralys Therapeutics Entrada Therapeutics Cartesian Therapeutics Humacyte Arcturus Therapeutics SNDL KalVista Pharmaceuticals ProKidney ABIVAX Société Anonyme Organogenesis Kyverna Therapeutics (NASDAQ:KYTX) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk. Is KYTX or MLYS more profitable? Kyverna Therapeutics' return on equity of -51.12% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kyverna TherapeuticsN/A -51.12% -37.91% Mineralys Therapeutics N/A -67.97%-62.40% Does the MarketBeat Community favor KYTX or MLYS? Mineralys Therapeutics received 6 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 66.67% of users gave Kyverna Therapeutics an outperform vote. CompanyUnderperformOutperformKyverna TherapeuticsOutperform Votes1066.67% Underperform Votes533.33% Mineralys TherapeuticsOutperform Votes16100.00% Underperform VotesNo Votes Do analysts prefer KYTX or MLYS? Kyverna Therapeutics currently has a consensus price target of $25.71, indicating a potential upside of 824.97%. Mineralys Therapeutics has a consensus price target of $27.00, indicating a potential upside of 182.43%. Given Kyverna Therapeutics' higher probable upside, equities analysts clearly believe Kyverna Therapeutics is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, KYTX or MLYS? Kyverna Therapeutics has higher revenue and earnings than Mineralys Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyverna Therapeutics$7.03M17.07-$60.37MN/AN/AMineralys TherapeuticsN/AN/A-$177.81M-$3.64-2.63 Does the media prefer KYTX or MLYS? In the previous week, Kyverna Therapeutics had 1 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 1 mentions for Kyverna Therapeutics and 0 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.34 beat Kyverna Therapeutics' score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Kyverna Therapeutics Neutral Mineralys Therapeutics Neutral Do insiders and institutionals believe in KYTX or MLYS? 18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 33.2% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryKyverna Therapeutics beats Mineralys Therapeutics on 8 of the 13 factors compared between the two stocks. Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYTX vs. The Competition Export to ExcelMetricKyverna TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$120.01M$3.13B$5.77B$8.99BDividend YieldN/A1.57%4.78%3.85%P/E RatioN/A30.1126.4618.82Price / Sales17.07386.80453.6978.73Price / CashN/A183.5344.0437.47Price / BookN/A3.567.634.64Net Income-$60.37M-$71.72M$3.18B$245.69M7 Day Performance-8.25%-2.46%-1.91%-2.66%1 Month Performance-15.50%-0.25%-0.19%-2.15%1 Year Performance-89.76%-12.31%16.70%12.90% Kyverna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYTXKyverna Therapeutics1.1679 of 5 stars$2.78-2.1%$25.71+825.0%-89.9%$122.61M$7.03M0.0096MLYSMineralys Therapeutics2.6396 of 5 stars$10.24+0.4%$27.00+163.7%-37.3%$509.65MN/A-3.1328TRDAEntrada Therapeutics3.3167 of 5 stars$13.44+6.4%$25.67+91.0%-2.0%$502.93M$215.23M8.45110Positive NewsRNACCartesian Therapeutics1.7124 of 5 stars$19.67+3.4%$42.86+117.9%-11.1%$500.01M$26M-0.3764HUMAHumacyte3.1294 of 5 stars$3.91-0.3%$13.71+250.7%-16.4%$492.11M$1.57M-2.92150Short Interest ↓ARCTArcturus Therapeutics2.6171 of 5 stars$18.05+10.0%$65.00+260.1%-49.6%$488.97M$169.93M-8.13180Gap UpHigh Trading VolumeSNDLSNDL3.5196 of 5 stars$1.86flat$3.25+74.7%+28.3%$488.77M$673.33M-6.002,516KALVKalVista Pharmaceuticals4.6917 of 5 stars$9.76+2.4%$23.80+143.9%-23.1%$482.34MN/A-2.68100Short Interest ↓News CoveragePROKProKidney1.3528 of 5 stars$1.61+0.6%$4.50+179.5%-1.3%$469.57MN/A-2.933Gap UpABVXABIVAX Société Anonyme2.0154 of 5 stars$7.40+3.2%$38.67+422.5%-33.4%$468.94MN/A0.0061News CoverageORGOOrganogenesis3.9616 of 5 stars$3.70+0.5%$5.00+35.1%-6.4%$465.20M$433.14M-61.67950News CoverageGap Up Related Companies and Tools Related Companies MLYS Alternatives TRDA Alternatives RNAC Alternatives HUMA Alternatives ARCT Alternatives SNDL Alternatives KALV Alternatives PROK Alternatives ABVX Alternatives ORGO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KYTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
